Literature DB >> 22124968

Genetic knockouts suggest a critical role for HIV co-receptors in models of HIV gp120-induced brain injury.

Ricky Maung1, Kathryn E Medders, Natalia E Sejbuk, Maya K Desai, Rossella Russo, Marcus Kaul.   

Abstract

Infection with HIV-1 frequently affects the brain and causes NeuroAIDS prior to the development of overt AIDS. The HIV-1 envelope protein gp120 interacts with host CD4 and chemokine co-receptors to initiate infection of macrophages and lymphocytes. In addition, the virus or fragments of it, such as gp120, cause macrophages to produce neurotoxins and trigger neuronal injury and apoptosis. Moreover, the two major HIV co-receptors, the chemokine receptors CCR5 and CXCR4, serve numerous physiological functions and are widely expressed beyond immune cells, including cells in the brain. Therefore, HIV co-receptors are poised to play a direct and indirect part in the development of NeuroAIDS. Although rodents are not permissive to infection with wild type HIV-1, viral co-receptors - more than CD4 - are highly conserved between species, suggesting the animals can be suitable models for mechanistic studies addressing effects of receptor-ligand interaction other than infection. Of note, transgenic mice expressing HIV gp120 in the brain share several pathological hallmarks with NeuroAIDS brains. Against this background, we will discuss recently completed or initiated, ongoing studies that utilize HIV co-receptor knockout and viral gp120-transgenic mice as models for in vitro and in vivo experimentation in order to address the potential roles of HIV gp120 and its co-receptors in the development of NeuroAIDS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22124968      PMCID: PMC3690779          DOI: 10.1007/s11481-011-9328-x

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  144 in total

Review 1.  Chemokines: a new classification system and their role in immunity.

Authors:  A Zlotnik; O Yoshie
Journal:  Immunity       Date:  2000-02       Impact factor: 31.745

Review 2.  The chimpanzee and other non-human-primate models in HIV-1 vaccine research.

Authors:  B M Nath; K E Schumann; J D Boyer
Journal:  Trends Microbiol       Date:  2000-09       Impact factor: 17.079

3.  Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice.

Authors:  S Toneatto; O Finco; H van der Putten; S Abrignani; P Annunziata
Journal:  AIDS       Date:  1999-12-03       Impact factor: 4.177

4.  Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120.

Authors:  R D'hooge; F Franck; L Mucke; P P De Deyn
Journal:  Eur J Neurosci       Date:  1999-12       Impact factor: 3.386

5.  Loss of neuronal integrity during progressive HIV-1 infection of humanized mice.

Authors:  Prasanta K Dash; Santhi Gorantla; Howard E Gendelman; Jaclyn Knibbe; George P Casale; Edward Makarov; Adrian A Epstein; Harris A Gelbard; Michael D Boska; Larisa Y Poluektova
Journal:  J Neurosci       Date:  2011-03-02       Impact factor: 6.167

6.  Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice.

Authors:  J Limoges; Y Persidsky; L Poluektova; J Rasmussen; W Ratanasuwan; M Zelivyanskaya; D R McClernon; E R Lanier; H E Gendelman
Journal:  Neurology       Date:  2000-01-25       Impact factor: 9.910

Review 7.  The chemokine network, a newly discovered target in high grade gliomas.

Authors:  U M Domanska; R C Kruizinga; W F A den Dunnen; H Timmer-Bosscha; E G E de Vries; A M E Walenkamp
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-14       Impact factor: 6.312

8.  Contrasting effects of CCR5 and CCR2 deficiency in the pulmonary inflammatory response to influenza A virus.

Authors:  T C Dawson; M A Beck; W A Kuziel; F Henderson; N Maeda
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

9.  CXCR4 mediates entry and productive infection of syncytia-inducing (X4) HIV-1 strains in primary macrophages.

Authors:  A Valentin; H Trivedi; W Lu; L G Kostrikis; G N Pavlakis
Journal:  Virology       Date:  2000-04-10       Impact factor: 3.616

10.  Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis.

Authors:  Larisa Y Poluektova; David H Munn; Yuri Persidsky; Howard E Gendelman
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

View more
  13 in total

Review 1.  Humanized mouse models for HIV-1 infection of the CNS.

Authors:  Jenna B Honeycutt; Patricia A Sheridan; Glenn K Matsushima; J Victor Garcia
Journal:  J Neurovirol       Date:  2014-11-04       Impact factor: 2.643

Review 2.  Modulatory Effects of Nicotine on neuroHIV/neuroAIDS.

Authors:  Haijun Han; Zhongli Yang; Sulie L Chang; Ming D Li
Journal:  J Neuroimmune Pharmacol       Date:  2018-09-13       Impact factor: 4.147

3.  Gp120 in the pathogenesis of human immunodeficiency virus-associated pain.

Authors:  Su-Bo Yuan; Yuqiang Shi; Jinghong Chen; Xiangfu Zhou; Guangyu Li; Benjamin B Gelman; Joshua G Lisinicchia; Susan M Carlton; Monique R Ferguson; Alai Tan; Sushil K Sarna; Shao-Jun Tang
Journal:  Ann Neurol       Date:  2014-05-28       Impact factor: 10.422

4.  CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward.

Authors:  Maciej Gonek; Virginia D McLane; David L Stevens; Kumiko Lippold; Hamid I Akbarali; Pamela E Knapp; William L Dewey; Kurt F Hauser; Jason J Paris
Journal:  Brain Behav Immun       Date:  2017-11-13       Impact factor: 7.217

Review 5.  The HIV-1 transgenic rat model of neuroHIV.

Authors:  Michael Vigorito; Kaitlyn P Connaghan; Sulie L Chang
Journal:  Brain Behav Immun       Date:  2015-02-27       Impact factor: 7.217

6.  Commentary: Animal models of neuroAIDS.

Authors:  Howard S Fox; Howard E Gendelman
Journal:  J Neuroimmune Pharmacol       Date:  2012-05-02       Impact factor: 4.147

7.  Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine.

Authors:  Brook L Henry; Mark A Geyer; Mahalah R Buell; William Perry; Jared W Young; Arpi Minassian
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

8.  Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice.

Authors:  Brook L Henry; Mark A Geyer; Mahalah Buell; William Perry; Jared W Young; Arpi Minassian
Journal:  Behav Brain Res       Date:  2012-08-31       Impact factor: 3.332

9.  Combination of methamphetamine and HIV-1 gp120 causes distinct long-term alterations of behavior, gene expression, and injury in the central nervous system.

Authors:  Melanie M Hoefer; Ana B Sanchez; Ricky Maung; Cyrus M de Rozieres; Irene C Catalan; Cari C Dowling; Victoria E Thaney; Juan Piña-Crespo; Dongxian Zhang; Amanda J Roberts; Marcus Kaul
Journal:  Exp Neurol       Date:  2014-09-20       Impact factor: 5.330

10.  Lipocalin-2 mediates HIV-1 induced neuronal injury and behavioral deficits by overriding CCR5-dependent protection.

Authors:  Daniel Ojeda-Juárez; Rohan Shah; Jerel Adam Fields; Indira S Harahap-Carrillo; Jeffrey Koury; Ricky Maung; Benjamin B Gelman; Bas J Baaten; Amanda J Roberts; Marcus Kaul
Journal:  Brain Behav Immun       Date:  2020-06-11       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.